Detail akcie Aptamer Grp Rg online

Business Summary: Aptamer Group plc is a United Kingdom-based global developer of aptamer-based ligands. The Company develops custom affinity binders through its Optimer platform to enable new approaches in therapeutics, diagnostics and research applications. The Company's Optimer platform delivers aptamer tools that are enabling researchers and developers across the spectrum of the life sciences. Its Optimer binders have been developed for a range of applications, including therapeutic inhibitors and modulators, drug delivery vehicles, protein purification and separation, biomarker screening and validation, in vitro research, quality control analysis, pharmacokinetic and drug assays, and in vitro diagnostic assays. Its Aptamer Diagnostics division uses the Company's technology to support the development of diagnostic platforms, such as proteomics, lateral flow devices, biosensors and immunoassays, such as enzyme-linked immunosorbent assay (ELISA).
Financial Summary: BRIEF: For the fiscal year ended 30 June 2025, Aptamer Group PLC revenues increased 40% to L1.2M. Net loss decreased 18% to L2.4M. Revenues reflect Europe segment increase from L14K to L239K, USA segment increase of 21% to L719K. Lower net loss reflects Administrative expenses decrease of 7% to L2.9M (expense), Other Operating Income increase of 24% to L158K (income).